As a neuraminidase inhibitor, oseltamivir (Tamiflu) mainly exerts its inhibitory effect on influenza virus, while drug interactions involve metabolic enzyme effects and clinical considerations for combination use. The following explanation will focus on pharmacological effects and drug interactions, with special attention paid to the risks associated with the combination of CYP450 enzyme related drugs.

1. Effect of action

(1) Antiviral mechanism: selectively inhibits influenza virus neuraminidase and prevents virus particle release.

(2) Timeliness: Medication within 48 hours of symptom onset can shorten the course of the disease by 1-3 days.

(3) Preventive effect: The effective rate of preventive medication after exposure can reach 70% -90%.

2. Drug interactions

(1) Probenecid: competes for renal tubular excretion, increasing the blood concentration of oseltamivir by 2 times.

(2) Influenza vaccine: Inactivated vaccines can be used simultaneously, while attenuated live vaccines require a 48 hour interval.

(3) CYP3A4 substrate: Oseltamivir may affect the concentration of drugs metabolized by this enzyme.

(4) P-gp inhibitors, such as verapamil, may increase the absorption of oseltamivir.

Special Notes

When combined with drugs such as osimertinib that pose a risk of QT interval prolongation, it is necessary to strengthen electrocardiogram monitoring. More clinical data is needed to support the specific interaction mechanism.